Cargando…

Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry

OBJECTIVE: The aim was to evaluate long-term drug retention, discontinuation, efficacy and safety of CT-P13 and reference infliximab in patients with rheumatoid arthritis (RA) enrolled in the Korean College of Rheumatology Biologics (KOBIO) registry. METHODS: Patients included adults with RA who rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyoun-Ah, Lee, Eunyoung, Lee, Sun-Kyung, Park, Yong-Beom, Lee, Young Nam, Kang, Hee Jung, Shin, Kichul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985057/ https://www.ncbi.nlm.nih.gov/pubmed/31734899 http://dx.doi.org/10.1007/s40259-019-00393-y

Ejemplares similares

Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2020)

Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2021)

Performance of the 2015 American College of Rheumatology/European League against Rheumatism Classification Criteria for Gout in Korean Patients with Acute Arthritis
por: Choi, In Ah, et al.
Publicado: (2019)

Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry
por: Kim, Min Jung, et al.
Publicado: (2022)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
por: Jung, Ju-Yang, et al.
Publicado: (2023)

Implications of Persistent Pain in Patients With Rheumatoid Arthritis Despite Remission Status: Data From the KOBIO Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2022)

Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide KOrean College of Rheumatology BIOlogics (KOBIO) registry
por: Jung, Seung Min, et al.
Publicado: (2018)

Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis
por: Kim, Ji-Won, et al.
Publicado: (2021)

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry
por: Koh, Jung Hee, et al.
Publicado: (2022)

COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
por: Park, Jin Kyun, et al.
Publicado: (2021)

Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
por: Kim, Se Hee, et al.
Publicado: (2021)

The Korean College of Rheumatology: 40 Years of Public Health Influence
por: Lee, Jisoo, et al.
Publicado: (2022)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
por: Di Giuseppe, Daniela, et al.
Publicado: (2021)

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
por: Studenic, Paul, et al.
Publicado: (2023)

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
por: Studenic, Paul, et al.
Publicado: (2022)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

A Population‐Based Study Evaluating Retention in Rheumatology Care Among Patients With Rheumatoid Arthritis
por: Barber, Claire E. H., et al.
Publicado: (2022)

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
por: Harrold, Leslie R., et al.
Publicado: (2016)

Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
por: Gheita, Tamer A., et al.
Publicado: (2023)

Korean College of Rheumatology: Forty Years of Excellence
por: Choe, Jung-Yoon, et al.
Publicado: (2022)

Biosimilars in rheumatology: understanding the rigor of their development
por: Goel, Niti, et al.
Publicado: (2017)

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study
por: Park, Jun Won, et al.
Publicado: (2022)

Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
por: Omair, Mohammed A., et al.
Publicado: (2022)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Erratum: Correction of Authors' Name Spelling in the Article “COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology”
por: Park, Jin Kyun, et al.
Publicado: (2021)

Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015)

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
por: Shin, Kichul, et al.
Publicado: (2022)

Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy
por: Kim, Hyoun-Ah, et al.
Publicado: (2022)

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13
por: Sakane, Hideo, et al.
Publicado: (2022)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
por: Cohen, Stanley B, et al.
Publicado: (2023)

Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Mortality in Korean Patients With Rheumatoid Arthritis
por: Lee, Yeon-Kyung, et al.
Publicado: (2021)

Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology
por: Mok, Chi Chiu, et al.
Publicado: (2010)

Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry
por: Prahalad, Sampath, et al.
Publicado: (2016)

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial
por: Park, Won, et al.
Publicado: (2018)

KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities
por: Kim, Jinhyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s326lujsn64q5menvc2aab9cv2